Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) EBIT (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of EBIT data on record, last reported at -$26.3 million in Q3 2025.

  • For Q3 2025, EBIT fell 102.03% year-over-year to -$26.3 million; the TTM value through Sep 2025 reached -$86.7 million, down 139.8%, while the annual FY2024 figure was -$42.6 million, 76.78% down from the prior year.
  • EBIT reached -$26.3 million in Q3 2025 per CAPR's latest filing, up from -$27.7 million in the prior quarter.
  • Across five years, EBIT topped out at -$1.3 million in Q4 2023 and bottomed at -$27.7 million in Q2 2025.
  • Average EBIT over 5 years is -$10.3 million, with a median of -$7.7 million recorded in 2023.
  • Peak YoY movement for EBIT: soared 84.12% in 2023, then plummeted 500.79% in 2024.
  • A 5-year view of EBIT shows it stood at -$6.4 million in 2021, then dropped by 26.44% to -$8.1 million in 2022, then skyrocketed by 84.12% to -$1.3 million in 2023, then tumbled by 500.79% to -$7.7 million in 2024, then tumbled by 241.45% to -$26.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$26.3 million in Q3 2025, -$27.7 million in Q2 2025, and -$25.0 million in Q1 2025.